pioglitazone has been researched along with Aortic Diseases in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Aortic Diseases: Pathological processes involving any part of the AORTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, D | 1 |
| Li, H | 1 |
| Zhou, R | 1 |
| Liu, MJ | 1 |
| Yu, H | 1 |
| Wu, DF | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Mizoguchi, M | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Nitta, Y | 1 |
| Kodama, N | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Kaida, H | 1 |
| Ishibashi, M | 1 |
| Hayabuchi, N | 1 |
| Harada, H | 1 |
| Ikeda, H | 1 |
| Yamagishi, S | 1 |
| Imaizumi, T | 1 |
| Marwick, TH | 1 |
| Narula, J | 1 |
| Gaillard, V | 1 |
| Casellas, D | 1 |
| Seguin-Devaux, C | 1 |
| Schohn, H | 1 |
| Dauça, M | 1 |
| Atkinson, J | 1 |
| Lartaud, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pioglitazone and Aortic Diseases
| Article | Year |
|---|---|
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
5 other studies available for pioglitazone and Aortic Diseases
| Article | Year |
|---|---|
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi | 2018 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |
Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.
Topics: Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Cyto | 2005 |